Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells

Sarah E. Church[1,2], Shawn M. Jensen[1], Paul A. Antony[3], Nicholas P. Restifo[4] and Bernard A. Fox[1,2,5]

[1] Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA

[2] Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA

[3] Department of Microbiology and Immunology, University of Maryland Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

[4] Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

[5] Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA

Immunotherapies that augment antitumor T cells have had recent success for treating patients with cancer. Here we examined whether tumor-specific CD4+ T cells enhance CD8+ T-cell adoptive immunotherapy in a lymphopenic environment. Our model employed physiological doses of tyrosinase-related protein 1-specific CD4+ transgenic T cells-CD4+ T cells and pmel-CD8+ T cells that when transferred individually were subtherapeutic; however, when transferred together provided significant ($p \leq 0.001$) therapeutic efficacy. Therapeutic efficacy correlated with increased numbers of effector and memory CD8+ T cells with tumor-specific cytokine expression. When combined with CD4+ T cells, transfer of total (naïve and effector) or effector CD8+ T cells were highly effective, suggesting CD4+ T cells can help mediate therapeutic effects by maintaining function of activated CD8+ T cells. In addition, CD4+ T cells had a pronounced effect in the early posttransfer period, as their elimination within the first 3 days significantly ($p < 0.001$) reduced therapeutic efficacy. The CD8+ T cells recovered from mice treated with both CD8+ and CD4+ T cells had decreased expression of PD-1 and PD-1-blockade enhanced the therapeutic efficacy of pmel-CD8 alone, suggesting that CD4+ T cells help reduce CD8+ T-cell exhaustion. These data support combining immunotherapies that elicit both tumor-specific CD4+ and CD8+ T cells for treatment of patients with cancer.

Keywords: Cancer immunotherapy · CD4+ T-cell help · Metastatic melanoma · PD-1 · T cell

Additional supporting information may be found in the online version of this article at the publisher's web-site

Introduction

Metastatic melanoma is a devastating disease with a poor overall survival rate. Two immunotherapies, IL-2 and anti-CTLA-4, provide objective clinical responses in approximately 15% of

patients and are approved drugs [1, 2]. Recently, the combination of anti-CTLA-4 and anti-PD-1 has shown to provide profound and rapid anticancer activity in approximately half of the patients receiving treatment [3]. Preclinical models have identified T-cell-dependent mechanisms as being the primary mediators of these antitumor effects [4]. Adoptive T-cell immunotherapy in patients made lymphopenic by nonmyeloablative chemotherapy has also provided significant success against this disease [5, 6]. Many

Correspondence: Dr. Bernard A. Fox
e-mail: foxb@foxlab.org

of these studies utilize T cells expanded from tumor-infiltrating lymphocyte (TIL) cultures; however, the use of human T cells transduced to express tumor-reactive TCRs or chimeric antigen receptors provides a practical alternative with the potential to be broadly applied to patients with almost any type of cancer [7, 8]. Furthermore, studies with chimeric antigen receptors have shown long-term tumor regression and tumor-specific T-cell persistence for over 6 months [7].

Both clinical trials and murine models, studying adoptive immunotherapy using tumor-specific TILs or TCR transgenic (Tg) T cells have shown that immunotherapy is more effective in a lymphopenic than in a lymphoreplete environment [5, 6]. A lymphopenic environment can be established in a number of ways including chemotherapy (cyclophosphamide), radiation, a combination of both or by using mice that lack endogenous T and B cells (RAG$^{-/-}$ deficient mice) [9, 10]. Each lymphopenia inducing method provides a different combination of mechanisms that enhances immunotherapy. In addition to the direct killing of tumor cells, by radiation or chemotherapy, mechanisms that augment T-cell expansion and effector function include elimination or absence of suppressive cells as well as cells that serve as cytokine sinks, increased access to antigen-presenting cells (APCs), and access to proinflammatory signals that may activate APCs or aid in overcoming T-cell exhaustion [11]. Additionally, combination adoptive immunotherapy that included induction of lymphopenia prior to adoptive transfer and IL-2 administration, has resulted in persistence of memory and circulating CD8$^+$ T cells and correlated with successful clinical outcome [12–14]. This supports the concept that CD8$^+$ T cells play a dominant role in tumor elimination by directly killing tumor cells or by the secretion of cytokine or chemokines that have antitumor effects and recruit other adaptive or innate immune components. Thus combinations that maintain or increase tumor-specific CD8$^+$ T cells would be expected to improve therapeutic efficacy [15].

The importance of CD4$^+$ T-cell help for both priming and maintenance of memory CD8$^+$ T-cell immunity has long been appreciated [16, 17]. Our lab and others have shown that immunotherapy with tumor-specific CD8$^+$ T cells in CD4-deficient MHC class II$^{-/-}$ mice resulted in regression of pulmonary metastases, but did not result in long-term antitumor immunity and tumors eventually recurred [18, 19]. In contrast, multiple studies have shown that partial or transient CD4-depletion can enhance antitumor responses, but since these models do not eliminate CD4$^+$ T cells completely, there may be a small population of CD4$^+$ T cells programming or maintaining CD8$^+$ T-cell function [20–22]. Moreover, induction of lymphopenia is thought to abrogate the need for CD4$^+$ help since it increases CD8$^+$ T-cell exposure to homeostatic cytokines, IL-7 and IL-15, driving memory T-cell formation and enhancing antitumor immune responses [23, 24].

Although it has not been directly examined, it is possible that low objective response rates in some studies are due to the transfer of tumor-specific CD8$^+$ T cells in the absence of tumor-specific CD4$^+$ T cells. Two studies utilizing MART-1 and/or gp100-specific HLA class I restricted TCR gene transfer for treatment of metastatic melanoma resulted in objective clinical response rates of 13%

(2/15) and 30% (6/20), which were lower than the response rates achieved using bulk CD4$^+$ and CD8$^+$ TILs (51–71%) . While these are small studies, one possible explanation for the low response rate is the absence of tumor-specific CD4$^+$ T cells. However, attempts to identify tumor-specific CD4$^+$ T cells in the peripheral blood of patients with cancer who experienced an objective clinical response following nonmyeloablative chemotherapy and adoptive immunotherapy with TILs have been difficult [25]. Furthermore, CD4$^+$ T cells alone have been expanded and adoptively transferred with high-dose IL-2 and have resulted in few clinical responses [26]. Given the prior studies underscoring the significant contribution, CD4$^+$ T cells play in supporting the therapeutic efficacy of tumor-specific CD8$^+$ T cells and a number of clinical studies suggesting that neither CD8$^+$ or CD4$^+$ T cells are effective alone, in this paper, we investigated the importance of tumor-specific CD4$^+$ T-cell help in augmenting antitumor immunity of CD8$^+$ T cells under conditions of lymphopenia-driven homeostasis.

Results

Immunotherapy with both pmel and TRP-1 augments therapeutic efficacy

Since adoptive transfer of large numbers (5×10^4–2×10^5) of tyrosinase-related protein 1-specific CD4$^+$ transgenic T cells (TRP-1) cytotoxic CD4$^+$ Tg T cells alone can induce regression of established B16-F10 melanoma [27, 28] we sought, to generate a model where therapeutic efficacy was dependent on both CD8$^+$ and CD4$^+$ T cells. Thus, we needed to identify a dose of TRP-1-CD4$^+$ Tg T cells that was not therapeutic on its own. To do this, 3-day experimental pulmonary metastases were established by i.v. injection of the poorly immunogenic subclone, B16BL6-D5 melanoma (D5) in tyrosinase-related protein 1 (tyrp-1)^{bw}RAG1$^{-/-}$ (RAG1$^{-/-}$ tyrp-1 protein deficient [29]) female mice, which lack endogenous T and B cells. Mice received adoptive transfer of CD4-enriched TRP-1 Tg cells at doses ranging from 1×10^6 to 50 cells. TRP-1-CD4$^+$ T cells failed to fully eliminate metastases regardless of their number, but animals treated with 5000 or less CD4$^+$ T cells had greater than 50 metastases (Supporting Information Fig. 1). Consequently, a dose of 1000 CD4-enriched TRP-1 cells, a physiologically relevant number, was used for subsequent experiments. For all experiments, gp100-specific CD8$^+$ Tg T cells (pmel) CD8$^+$ T cells were activated by αCD3/IL-2 expansion. RAG1$^{-/-}$ tyrp1 protein-deficient lymphopenic mice with 3-day D5 experimental pulmonary metastases were treated with 10^6 αCD3/IL-2-expanded pmel and 1000 naïve CD4-enriched TRP-1 (Pmel + TRP-1), 10^6 αCD3/IL-2-expanded pmel alone, 1000 TRP-1 alone or no treatment (Fig. 1A). All mice received 90 000 IU IL-2 i.p. daily for 3 days. Ten and 20 days after adoptive transfer mice treated with both pmel and TRP-1 cells had significantly less tumor burden than mice treated with either pmel or TRP-1 alone (Fig. 1B). Mice treated with both pmel and TRP-1 showed no evidence of tumor after 40 days, while pmel or TRP-1 alone groups succumbed to tumor burden before 27 days (Fig. 1C).

Figure 1. Treatment with tumor-specific pmel and TRP-1 T cells of lymphopenic tumor-bearing RAG1$^{-/-}$ mice eliminates tumor and increases pmel T cells in the blood and spleen. (A) Overview of RAG1$^{-/-}$ lymphopenic experimental pulmonary metastases model. RAG1$^{-/-}$ lymphopenic tyrp1 protein-deficient mice were treated with 2×10^5 D5 melanoma cells i.v. After 3 days, the same mice were treated with 1×10^6 αCD3/IL-2 stimulated pmel-CD8$^+$ Tg cells and 1000 CD4-enriched TRP-1 Tg cells (Pmel + TRP-1), pmel alone (Pmel), TRP-1 alone (TRP-1) or no cells (IL-2 only). All mice also received 3 doses of 90 000 IU IL-2 i.p. daily. Mice were euthanized (†) for analysis 10, 20, and 40 days after adoptive immunotherapy. (B) Number of pulmonary metastases at each time point with representative resected lungs. (C) Total number of CD3$^+$CD4$^+$ or CD3$^+$CD8$^+$ cells in the blood or spleen at day 10, 20, and 40 following adoptive immunotherapy. (A and B) Data are shown as mean ± SEM of $n = 9$–20 mice per time point and are combined from four independent experiments. *$p < 0.001$; Students t-test.

Treatment with both pmel and TRP-1 significantly increased the number of CD8$^+$ T cells in the blood and the spleen 10 and 20 days following adoptive transfer, compared to treatment with pmel alone (Fig. 1C). This is notable because persistence of anti-tumor CD8$^+$ T cell has been correlated with long-term tumor control [2, 30, 31]. Treatment with pmel and TRP-1 also resulted in increased CD4$^+$ T cells in the blood compared to TRP-1 treatment alone; however, there were decreased CD4$^+$ T cells in the spleen (Fig. 1C).

The addition of TRP-1 T cells enhances the number and function of pmel-CD8$^+$ T cells

CD4$^+$ T cells are known to be important for maintenance of effector (T$_{Eff}$) and memory (T$_{memory}$) CD8$^+$ T cells [5], therefore, we

determined whether adoptive transfer of both pmel and TRP-1 T cells increased the number and frequency of T$_{memory}$ and T$_{Eff}$ pmel-CD8$^+$ T cells compared to adoptive transfer with pmel alone. Mice receiving combined therapy exhibited an increased total number of T$_{Eff}$ (CD44$^+$CD62L^{lo}CD127^{lo}) pmel-CD8$^+$ T cells in the blood and spleen (Fig. 2A). There was also an increase in total T$_{memory}$ (CD44$^+$CD127$^+$) pmel-CD8$^+$ T cells in the blood and effector memory (T$_{EM}$) (CD44$^+$CD127$^+$CCR7^{lo}) pmel-CD8$^+$ T cells in the spleen.

The composition of naïve (CD62L$^+$CD44^{lo}), T$_{Eff}$ (CD44$^+$CD127^{lo}CCR7^{lo}), T$_{EM}$ (CD44$^+$CD127$^+$CCR7^{lo}), and central memory (T$_{CM}$) (CD44$^+$CD127$^+$CCR7$^+$) pmel-CD8$^+$ T cells 10 and 20 days after adoptive transfer indicates a much smaller proportion of T$_{EM}$ phenotype pmel-CD8$^+$ T cells in mice treated with pmel T cells alone (Fig. 2B). The presence of tumor-specific TRP-1-CD4$^+$ T cells increased the number and

Figure 2. Treatment of tumor-bearing RAG1$^{-/-}$ mice with tumor-specific pmel and TRP-1 T cells increases survival and function of T$_{Eff}$ and T$_{memory}$ pmel T cells. (A) T$_{Eff}$ (CD44$^+$CD62L^{lo}CD127^{lo}) and T$_{memory}$ (CD44$^+$CD127$^+$) CD8$^+$ or CD4$^+$ T cells in the blood and T$_{Eff}$ and T$_{EM}$ (CD44$^+$CD62L^{lo}CD127$^+$CCR7^{lo}) in the spleen 10 and 20 days after adoptive immunotherapy with both pmel and TRP-1 compared to treatment with pmel alone or TRP-1 alone. (B) Distribution of T$_{naïve}$, T$_{Eff}$, T$_{EM}$ (EM), and T$_{CM}$ (CM) phenotype CD8$^+$ or CD4$^+$ T cells in the spleen at the day of transfer (day 0), 10 or 20 days after adoptive transfer. (C) Percent of tumor-specific IFN-γ expressing CD8$^+$ or CD4$^+$ T cells stimulated with specific D5 CIITA (D5II), nonspecific syngeneic MCA-310 CIITA (MCAII) or unstimulated (no stim) 20 days after adoptive immunotherapy. (A–C) Data are shown as mean ± SEM of $n = 9$–20 mice per time point and are combined from four independent experiments. $^*p < 0.001$, Student's t-test. (D) ICS of CD8$^+$-gated cells using splenocytes from pmel + TRP-1 or pmel-treated mice stimulated with αCD3 or unstimulated. Representative pies from one experiment out of four performed.

frequency of pmel T$_{Eff}$ CD8$^+$ T cells that eliminated the tumor and also increased the number of long-lived memory T cells (Fig. 2A and B). Analysis of CD8$^+$ T-cell function by intracellular cytokine staining 10 days after transfer, showed that pmel-CD8$^+$ T cells from pmel and TRP-1-treated mice had a significantly ($p \leq 0.001$) higher frequency of D5-specific IFN-γ-expressing cells compared to stimulation with the syngeneic but unrelated MCA-310 sarcoma. However, CD8$^+$ T cells from pmel-only-treated mice also exhibited an increased percentage of IFN-γ-positive pmel-CD8$^+$ T cells, but this difference did not reach statistical significance (Fig. 2C). Pmel and TRP-1-treated mice also had a higher frequency of CD8$^+$ T cells exhibiting polyfunctional cytokine expression (TNF-α, IFN-γ, Granzyme B, and IL-2), which has been associated with long-lived T cells (Fig. 2D) [8, 32–34]. We analyzed the phenotype of TRP-1-CD4$^+$ T cells in blood and spleen and found increased numbers of T$_{Eff}$ and T$_{EM}$ in TRP-1-only treated mice compared to pmel and TRP-1-treated mice (Fig. 2A). There were significantly more T$_{Eff}$ TRP-1-CD4$^+$ T cells in the blood of pmel- and TRP-1-treated mice, however, this was only

at the day 20 time point and did not translate to a proportional difference in the entire population (naive, T$_{Eff}$, T$_{EM}$, and T$_{CM}$) as we observed in the CD8$^+$ T cells (Fig. 2A and B). Mice treated with either pmel and TRP-1 or TRP-1 only had an equal percentage of tumor-specific IFN-γ-producing CD4$^+$ T cells (Fig. 2C). Since previous studies using the D5 experimental metastases model documented that CD8$^+$ T cells were the dominant mechanism for eliminating tumor when endogenous tumor vaccine-primed T cells were used for adoptive immunotherapy, we focused on the effect CD4$^+$ T cells had on the CD8$^+$ T cells [7, 35].

TRP-1 T cells help maintain pmel-CD8$^+$ T cells

We found that following adoptive transfer of tumor-specific Tg CD4$^+$ and CD8$^+$ T cells, tumor had not recurred by 40 days and most animals were apparently cured of their disease (Fig. 1B and data not shown). We hypothesized that CD4$^+$ T cells could be helping to prime a small number of T$_{naïve}$ CD8$^+$ T cells that

still remain after αCD3/IL-2 expansion. Therefore, we phenotyped αCD3/IL-2-expanded pmel at the time of adoptive immunotherapy (day 0). This analysis revealed a large population (15–20%) of phenotypically "naïve" (CD44^{lo}CD62L$^+$) CD8$^+$ T cells (referred to as αCD3/IL-2 expanded CD44^{lo}CD62L$^+$) (Fig. 2B). This observation surprised us, so we examined whether CD4$^+$ T cells needed this αCD3/IL-2-expanded CD44^{lo}CD62L$^+$ population to help prime CD8$^+$ T cells or whether they were maintaining activated T$_{Eff}$ phenotype CD8$^+$ T cells. To test this, we eliminated the CD44^{lo}CD62L$^+$ CD8$^+$ T cells from the αCD3/IL-2 expanded population by sorting on T$_{Eff}$ phenotype pmel (CD44$^+$CD62L^{lo}). We then compared treatment with 5×10^5 sorted effector CD44$^+$CD62L^{lo} pmel and 1000 TRP-1 T cells (sort Pmel+ TRP-1), 5×10^5 sorted T$_{Eff}$ CD44$^+$CD62L^{lo} pmel alone (sort Pmel), 5×10^5 total αCD3/IL-2-expanded pmel and TRP-1 (total Pmel + TRP-1) or 5×10^5 total pmel alone (total Pmel) (Supporting Information Fig. 2B).

Immunotherapy with sorted T$_{Eff}$ pmel or total pmel, combined with TRP-1 T cells had significantly less tumor growth at 10 and 20 days following treatment compared to mice treated with either pmel population alone (Fig. 3A). The majority of mice treated with both pmel and TRP-1, either sorted or total, survived longer than 40 days with no symptoms of tumor progression (Fig. 3B). Furthermore, while mice treated with sorted pmel and TRP-1 had fewer splenic CD8$^+$ T cells than mice receiving total pmel and TRP-1, their numbers were still increased compared to mice treated with only total or sorted pmel T cells 10 days after transfer (Fig. 3C). Since elimination of the αCD3/IL-2 expanded CD44^{lo}CD62L$^+$ did not diminish the antitumor effects in vivo, it suggests that tumor-specific TRP-1-CD4$^+$ T cells are able to maintain activated pmel-CD8$^+$ T cells.

Furthermore, comparison of proliferation and function of ex vivo αCD3/IL-2-expanded CD44^{lo}CD62L$^+$, αCD3/IL-2-expanded T$_{Eff}$ CD44$^+$CD62L^{lo} cells, and unstimulated pmel splenocytes showed that αCD3/IL-2 expanded CD44^{lo}CD62L$^+$ and T$_{Eff}$ CD44$^+$CD62L^{lo} pmel cells proliferated ($>5\times$) and showed comparable functionality (IFN-γ$^+$TNFα$^+$) whereas unstimulated pmel splenocytes did not (Supporting Information Fig. 3). These data support that tumor-specific CD4$^+$ T cells can act in conjunction with T$_{EM}$ CD8$^+$ T cells to increase their numbers, tumor-specific function and efficacy, even in the absence of naïve T-cell priming.

TRP-1 help occurs early after adoptive immunotherapy

We attempted to determine when, in relation to adoptive transfer, tumor-specific CD4$^+$ T cells were needed to maintain antitumor immunity. According to the model described in Figure 1A, CD4$^+$ cells were depleted 1 day prior, 3 and 10 days following adoptive immunotherapy with pmel and TRP-1 cells. Anti-CD4 antibody was administered 1 day prior to adoptive transfer even though RAG1$^{-/-}$ mice have no T cells to ensure CD4$^+$ cells were immediately eliminated upon transfer. We expected this to

replicate adoptive transfer with pmel alone. Indeed, depletion of CD4$^+$ cells 1 day prior to adoptive immunotherapy resulted in a large tumor burden that was similar to pmel treatment alone. CD4-depletion 10 days after transfer resulted in less tumor burden, similar to undepleted mice, depletion at day 3 gave results that were intermediate (Fig. 4A). This suggests that in this model tumor-specific CD4$^+$ T cells exert their effects during the first 10 days following adoptive transfer. We examined whether CD4 depletion changed the number of CD8$^+$ T cells in the blood and spleen 17/18 days after immunotherapy, CD4-depleted groups showed a substantial decrease in the number of pmel-CD8$^+$ T cells (Fig. 4B and data not shown). We also looked at expression of the exhaustion marker PD-1 (J43 antibody) on splenocytes 17/18 days after adoptive transfer. PD-1 expression on pmel-CD8$^+$ T cells was significantly higher among CD8$^+$ cells in all nontherapeutic CD4-depleted groups (Day 1, 3 and pmel alone) than in CD8$^+$ cells from undepleted mice (Fig. 4C). Depletion of CD4$^+$ cells 1 day before or 3 days after adoptive transfer also correlated with decreased expression of IFN-γ, IL-2, TNF-α, and Granzyme B measured at day 17/18, compared to deletion at day 10 or undepleted mice (Fig. 4D). However, long-term antitumor immunity was still compromised in mice depleted of CD4$^+$ T cells 10 days after transfer compared to undepleted mice (Fig. 4E). Interestingly, mice depleted of CD4$^+$ cells 10 days after transfer often developed tumors at metastatic sites, such as the skin (Fig. 4E). This suggests that CD4$^+$ T cells continue to maintain pmel-CD8$^+$ T cells or potentially act to support trafficking of CD8$^+$ T cells in order to control tumor metastases [36].

PD-1-blockade augments the therapeutic efficacy of pmel-CD8$^+$ T cells

We next examined whether blocking PD-1 could restore the therapeutic efficacy of pmel T cells alone by treating mice with a PD-1-blocking antibody. PD-1-blockade augmented therapeutic efficacy of pmel T cells alone, significantly ($p < 0.01$) reducing the number of metastases compared to pmel T cells alone (31 ± 5 versus 82 ± 16 mean $\pm$ SEM) (Fig. 5A). Since PD-1 treatment did not result in complete elimination of metastases, we examined other mechanisms of CD4$^+$ T-cell help including CD40-CD40L, increasing survival or decreasing apoptosis [37–39]. There was no difference in overall survival or in the total number and function of T cells with CD40-CD40L blockade (Supporting Information Fig. 4) suggesting that in our model enhancement of CD8$^+$ T cells was not dependent on CD40–CD40L interactions. We also examined expression of the survival factor Bcl-2 and the apoptotic factor TRAIL in CD8$^+$ T cells from pmel and TRP-1 or pmel-alone-treated mice. There was no difference in Bcl-2 expression; however, there was a substantial decrease in TRAIL expression when mice were treated with both pmel and TRP-1 T cells (Fig. 5B), implying the addition of tumor-specific CD4$^+$ T cells increases CD8$^+$ T-cell persistence by reducing exhaustion by the PD-1 pathway and decreasing TRAIL-induced apoptosis.

Figure 3. Tumor-specific TRP-1 T cells are important for maintaining activated pmel in the lymphopenic environment. (A and B) Mice were treated with 5×10^5 αCD3/IL-2-expanded sorted T_{Eff} (CD44$^+$CD62L^{lo}) pmel and 1000 TRP-1 cells (sort pmel + TRP-1), 5×10^5 total CD3/IL-2-expanded pmel and 1000 TRP-1 (total pmel + TRP-1), sort pmel alone or total pmel alone. (A) Number of pulmonary metastases 10 and 20 days after adoptive transfer. Data are shown as mean ± SEM of $n = 3$ mice per group and are representative of one out of two independent experiments. *$p < 0.05$, **$p < 0.01$; Student's t-test (B) Numbers are mice that are tumor free of total. Data shown are from five to six mice and combined from two independent experiments. (C) Total number of CD3$^+$CD8$^+$ T cells with distribution of T_{Eff}, T_{EM}, and T_{CM} phenotypes in the spleen 10 days after immunotherapy. Data shown are one representative of two independent experiments.

Discussion

We recently found that tumor-vaccine-specific CD4$^+$ T cells augmented therapeutic efficacy of immunotherapy with tumor-specific CD8$^+$ T cells in the RAG1$^{-/-}$ lymphopenic environment (Friedman, manuscript in preparation). Here we take advantage of the tumor-specific TRP-1 MHC class II-restricted TCR Tg CD4$^+$ T cells to examine the role of tumor-specific CD4$^+$ T cells in the lymphopenic environment. Our results suggest that tumor-specific CD4$^+$ T cells in combination with tumor-specific CD8$^+$ T cells augment therapeutic efficacy, maintain long-term tumor control, and increase total survival and function of CD8$^+$ T cells. Additionally, we show that physiological doses of tumor-specific CD4$^+$ T cells could significantly ($p < 0.001$) augment therapeutic efficacy of immunotherapy with tumor-specific CD8$^+$ T cells (Fig. 1B). Treatment with both pmel and TRP-1 increased tumor-specific function, polyfunctionality, and total number of effector and memory CD8$^+$ T cells compared to pmel alone (Fig. 1C and 2). This suggests tumor-specific CD4$^+$ T cells enhance memory, survival, and effector function of tumor-specific CD8$^+$ T cells. Adoptive immunotherapy with low doses of TRP-1-CD4$^+$ cells used here did not result in significant therapeutic efficacy (Fig. 1B). However, the TRP-1-only treated mice had significantly more CD4$^+$ T cells in the spleen than pmel- and TRP-1-treated mice 10 and 20 days after transfer (Fig. 1C and 2A). This suggests that even though there are more CD4$^+$ T cells in the spleen with TRP-1 treatment alone, the CD4$^+$ T cells are less effective at eliminating tumor, possibly because they are trafficking to the spleen rather than the tumor.

Our data also suggest that tumor-specific CD4$^+$ T cells can support therapeutic efficacy by maintaining effector CD8$^+$ T cells even in the absence of phenotypically naïve CD8$^+$ T cells (Fig. 3 and Supporting Information Fig. 3). Ten days after transfer mice given TRP-1 and CD44$^+$CD62L$^-$ pmel had less total CD8$^+$ T cells than those treated with TRP-1 and total pmel; however, this num-

ber was considerably more than either group treated with pmel alone (Fig. 3C) and TRP-1 and CD44$^+$CD62L$^-$ pmel-treated mice did not develop tumor after more than 70 days (Fig. 3A and B). This ability of CD4$^+$ and CD8$^+$ T cells to cure mice of systemic tumor burden in the absence of a source of naïve CD8$^+$ T cells is strong evidence that CD4$^+$ T cells are maintaining CD8$^+$ effector T cells in this model. Characterizing αCD3/IL-2 ex vivo expanded pmel showed that αCD3/IL-2-expanded CD44^{lo}CD62L$^+$ cells were expressing some TNF-α and IFN-γ and proliferating similarly to the T_{Eff} phenotype cells (Supporting Information Fig. 3). One explanation for this apparent disconnect between phenotype and production of effector cytokines could be that CD62L and CD44 are being upregulated and downregulated during the αCD3/IL-2 stimulation causing them to display an atypical phenotype, including a population of CD44^{lo}CD62L^{lo} cells that are neither a $T_{naïve}$ (CD44^{lo}CD62L$^+$) or T_{Eff} (CD44$^+$CD62L^{lo}) phenotype (data not shown). If this is the case, it further supports that tumor-specific TRP-1 CD4$^+$ T cells are acting to maintain activated CD8$^+$ T cells in the lymphopenic environment.

Tumor-specific TRP-1-CD4$^+$ T cells were particularly important early following adoptive transfer, as elimination within 3 days, but not 10 days (Fig. 4A) resulted in partial loss of therapeutic efficacy and correlated with an increase in the exhaustion marker PD-1 on CD8$^+$ T cells at day 18. The increase of PD-1 was most significant for the group depleted of CD4$^+$ cells 3 days after transfer (Fig. 4C), suggesting that the early time points may be particularly important for CD4$^+$ help. These findings are consistent with reports showing that antigen-specific CD4$^+$ T-cell help can decrease PD-1 expression on CD8$^+$ T cells [20,40–42]. Elimination of CD4$^+$ cells 10 days after adoptive transfer did not reduce therapeutic efficacy, measured by enumeration of pulmonary metastases at day 18 or result in increased PD-1 expression on CD8$^+$ T cells compared to undepleted mice. However, we did see a decrease in total number of pmel-CD8$^+$ T cells in the day 10 depleted group. One possible explanation is that by day 10, when the CD4$^+$

Figure 4. TRP-1 T cells are important early to reduce tumor burden. Mice treated with pmel and TRP-1 were depleted of CD4 cells one day prior, 3 or 10 days following adoptive transfer and compared to pmel alone or no treatment. All analysis was done 17/18 days following immunotherapy. (A) Total number of pulmonary metastases 17/18 days after adoptive transfer and survival. (B) Total number of CD3$^+$CD8$^+$ T cells in the spleen. (C) Frequency of PD-1 expressing CD3$^+$CD8$^+$ T cells 17/18 days after transfer. Histogram shows representative PD-1 expression on CD3$^+$CD8$^+$ cells comparing treatment with rat IgG treatment or CD4-depletion 3 days after transfer. (D) Summary of the number of cytokines expressed by CD8$^+$ T cells (IL-2, TNF-α, IFN-γ, and Granzyme B) with 24 h αCD3 or no stimulation. (E) Survival curve and representative of distant skin metastases that occurred 38 days after transfer in mice depleted of CD4$^+$ T cells 10 days after transfer. (A–C) Data are shown as mean $\pm$ SEM of $n = 3$–4 mice per group and are two combined experiments performed with all groups out of three independent experiments $^*p < 0.05$, $^{**}p < 0.01$; one-way ANOVA. (D and E) Data are one representative experiment of three independent experiments.

T cells are depleted, the majority of tumor has been eliminated and there is less antigen-driven proliferation of CD8$^+$ T cells. Both undepleted mice and day 10 depleted mice also had polyfunctional (IFN-γ, TNF-α, Granzyme B, IL-2) CD8$^+$ T cells, 17/18 days after adoptive transfer, which may be responsible for the enhanced antitumor efficacy at this time point (Fig. 4D). Interestingly, eliminating CD4$^+$ T cells 10 days after adoptive transfer resulted in late-onset distant metastases (skin, ovaries) 40 days after transfer (Fig. 4E). This development of distant metastases is consistent with one previous study using adoptive immunotherapy with CD8$^+$ T cells in MHC class II-deficient mice [18]. Distant tumor metastases were not observed in mice that received both pmel and TRP-1 (undepleted), even 200 days after immunotherapy and might be explained by the role of CD4$^+$ T-cell help in CD8$^+$ T-cell trafficking, which has been observed in other models [36, 43] or that CD4$^+$ help is maintain-

ing memory CD8$^+$ T cells, which are important for tumor immune surveillance [44].

Investigating the mechanism of this CD4 support, we identified that PD-1 interactions play a role in limiting the antitumor effects of immunotherapy with nonhelped pmel-CD8$^+$ T cells, as PD-1 blockade significantly ($p < 0.01$) improved therapeutic efficacy (Fig. 5A). In contrast, blockade of CD40–CD40L interactions in animals treated with both tumor-specific CD4$^+$ and CD8$^+$ T cells did not decrease therapeutic efficacy, suggesting that these interactions are not essential (Supporting Information Fig. 4). Such an independence of CD40–CD40L interactions has been described in a number of other preclinical cancer immunotherapy models [35]. Further, phenotypic characterization of T cells at times following adoptive transfer suggest tumor-specific TRP-1-CD4$^+$ T cells maintain pmel-CD8$^+$ T cells, in the lymphopenic environment, by decreasing TRAIL expression (Fig. 5B). Together these data

Figure 5. PD-1-blockade augments the therapeutic efficacy of pmel alone. (A) Number of pulmonary metastases from mice treated with pmel plus PD-1-blocking antibody (RMP1–14) or rat IgG. All mice received IL-2 (B). Mice treated with pmel and TRP-1 cells were compared to mice treated with pmel alone. Flow cytometry is shown for Live-CD3$^+$CD8$^+$ cells 18 days after adoptive transfer. MFI minus control (FMO) of Bcl-2 and TRAIL. Histograms representative TRAIL expression for pmel and TRP-1 or pmel-alone-treated mice. Black line is treatment, gray fill is FMO. Data are shown as mean ± SEM of (A) n = 3–6 or (B) n = 3 mice and are combined from (A) three or (B) two independent experiments. Statistics are (A) one-way ANOVA or (B) Students t-test.

suggest that tumor-specific CD4$^+$ T cells are important to reduce PD-1-mediated exhaustion and potentially TRAIL-mediated apoptosis during initial tumor elimination.

Approximately 33% of all pmel- and TRP-1-treated mice developed amelanotic tumors, 100–200 days after adoptive transfer, at the primary metastatic site in the pleural cavity (data not shown). This frequency of amelanotic tumor recurrence in mice treated with pmel and TRP-1 T cells is consistent with a recent report from Jensen et al. evaluating recurrence of experimental subcutaneous melanoma [45]. In our study, mice that recurred with amelanotic tumor had a decreased total number and function of CD4$^+$ and CD8$^+$ T cells, and tumor cells had reduced expression of

gp100 and TRP-1 protein (data not shown). This indicates antigen loss is a potential problem and antigen-specific CD4$^+$ and CD8$^+$ T cells may need additional combination therapy to prevent tumor recurrence or should consider targeting antigens that are critical to tumor's survival. Furthermore lymphoreplete mice made lymphopenic by radiation and given immunotherapy with the same number of TRP-1 and pmel that were therapeutic in Rag1$^{-/-}$ mice, did not experience a significant reduction in tumor burden (Supporting Information Fig. 5). These findings underscore the complexities of the immune response and the preclinical model systems and identify opportunities for studies that may uncover novel mechanisms that limit antitumor immunity. Given our findings of the important role tumor-specific CD4 T cells play in augmenting therapy, combining CD8$^+$ T-cell adoptive immunotherapy with vaccination that includes targets with CD4$^+$ epitopes may be a good way to induce endogenous tumor-specific CD4$^+$ helper T-cell responses. This approach has the theoretical advantage of developing a broad range of CD4$^+$ T cells by targeting multiple tumor antigens or by eliciting epitope spreading of endogenous CD4$^+$ T cells [46, 47]. This broad CD4$^+$ T-cell repertoire might reduce the significance of tumor antigen-loss variants, which are seen in multiple preclinical models where a single antigen is targeted [47]. Together our data strongly argues that tumor-specific CD4$^+$ T cells play an important role in maintaining long-term systemic antitumor immunity and suggest that investigators designing clinical immunotherapy trials should consider a range of vaccine or adoptive immunotherapy options that include or promote both tumor-specific CD4$^+$ and CD8$^+$ T cells in order to optimize clinical outcome of patients on these trials.

Materials and methods

Tumor cell lines and metastases

We used the poorly immunogenic subclone, D5, isolated from the spontaneously arisen B16BL6 melanoma. This tumor cell line is defined as poorly immunogenic as vaccination with irradiated D5 fails to protect mice from a subsequent challenge with viable D5 [48]. MCA-310 or D5-G6, a D5 clone stability transduced to secrete GM-CSF were used to generate MCA-310 or D5-specific CD4$^+$ T cells, as previously described [18]. T-cell stimulation assays were done using D5 CIITA and the unrelated syngeneic sarcoma MCA-310 CIITA; both were modified to express CIITA [6]. D5, D5-G6, D5 CIITA, and MCA-310 CIITA were propagated using 10% FBS RPMI 1640 supplemented with 2 mmol/L L-glutamine, 0.1 mmol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 5 µg/mL gentamicin-sulfate (Lonza), and 50 µM/L β-mercaptoethanol (Sigma). All tumor cell lines were propagated for less than 6 weeks. Three-day established pulmonary metastases were generated by injecting 2 × 10^5 D5 cells i.v.

Mice and adoptive immunotherapy

TRP-1 TCR × tyrp-1^{bw}RAG$^{-/-}$ (RAG1$^{-/-}$ tyrp1 protein-deficient MHC Class II-restricted TCR Tg) male mice were used to isolate tumor-specific TRP-1-CD4$^+$ splenocytes (gift from Dr. Restifo and The Jackson Laboratory). TRP-1-CD4$^+$ T cells are specific for the murine tyrosinase related protein 1 peptide (36). Tyrp-1 protein is expressed by the B16BL6-D5 and TRP-1-CD4$^+$ T cells secrete IFN-γ in response to stimulation with class II$^+$ D5 tumor cells. Female RAG1$^{-/-}$ tyrp1-protein-deficient littermates, which lack the TCR transgene or RAG1$^{-/-}$ were used as hosts. RAG1$^{-/-}$ pmel-1 (MHC class I-restricted TCR Tg) mice were generated by breeding RAG1$^{-/-}$ (The Jackson Laboratory) with pmel-1 mice (gift of Dr. Restifo), and used to isolate pmel tumor-specific CD8$^+$ T cells from male mice.

Recognized principles of laboratory animal care were followed (Guide for the Care and Use of Laboratory Animals, National Research Council, 1996) and all animal protocols were approved by the EACRI animal care and use committee.

Single-cell suspensions of pmel splenocytes were incubated for 2 days on 5 μg/mL anti-CD3 (2C11) in a 24-well plate followed by 3 days with 60 IU/mL IL-2 (Chiron) in a lifecell tissue culture bag (Baxter) (referred to as αCD3-IL-2-expansion). TRP-1-CD4$^+$ splenocyte suspensions were enriched using a pan T-cell isolation kit (Miltenyi). Intravenous injections used 10^6 αCD3/IL-2-expanded pmel and/or 1000 enriched TRP-1 cells, unless otherwise noted. Mice also received i.p. injections of 90,000 IU IL-2 (Chiron) given daily for 3 days. Mouse lungs were resected and stored in Feketes solution. Metastases were enumerated by counting black nodules on the lung surface. Maximum tumor burden was recorded as 200 metastases.

Flow cytometry

Spleens were disrupted using a 3-mL syringe in a 6-well plate and filtered to single-cell suspensions. Red blood cells were lysed using ACK buffer (Lonza). Cells were stained for phenotyping and sorting with combinations of the following antibodies CD4-Qdot605 (Invitrogen), CD8-PE-Cy7, CD3-Percp-eFluor710, CD62L-Pacific blue/eFluor450, CD127-PE, CD127-allophycocyanin-eFluor780, PD-1-FITC, CCR7-allophycocyanin, CD44-AF700, PD-1-PE, TRAIL-PE, Bcl-2-FITC, FOXP3-eFluor450 (eBioscience), CD4-allophycocyanin-Cy7, CD4-allophycocyanin-H7 (Becton Dickinson). PD-1 staining was done on splenocytes harvested 17/18 days after adoptive transfer using the anti-PD-1 (J43) antibody. Intracellular staining was performed using the eBioscience fix-perm kit. The gating strategy for memory T cells is shown in Supporting Information Fig. 2A.

Blood counts were calculated using Flow-Count Fluorospheres (Beckman Coulter). For intracellular cytokine staining, splenocytes were incubated 18–24 h adding 5 μg/mL Brefeldin A (Sigma) after 2 h. Cells were stained with LIVE/DEAD fixable yellow stain (Invitrogen-Molecular Probes), CD8-V500 and CD4-APC-H7 (Becton Dickinson). Cells were fixed and permeablized (Becton Dickinson) and then stained with IFN-γ-PE (Becton Dickinson), TNFα-FITC, Granzyme-B-PE-Cy7, and/or IL-2-eFluor450/Pacific Blue (eBioscience) or IL-2-Brilliant Violet 421 (Biolegend). ICS cells were gated on live-singlet lymphocytes negative for live-dead dye, followed by CD4$^+$ or CD8$^+$ and individual cytokines. Proliferation was detected using CFSE (Invitrogen-Molecular Probes) as previously reported [49]. Gates were based on fluorescence minus one controls. All samples were run on a BD LSRII or BD Aria and analyzed using FlowJo (Treestar), Pestle, and SPICE (Courtesy of Mario Roederer).

Depletion and blocking antibodies

CD4- and CD8-depleting antibodies were made from 2.43 or GK1.5 hybridomas (ATCC), respectively by purifying ascites using Biosephra MEP Hypercel (Ciphergen) as described previously [35] or purchased (BioXcell). CD40L-blocking antibody (MR1), PD-1 (RMP1–14) and hamster IgG were purchased (BioXcell). Rat IgG control antibody was purchased (Sigma).

Statistics

Unpaired, paired Student's *t*-tests, or one-way ANOVAs were done for analysis of cell numbers and phenotype using Prism (Graphpad). Mantel-Cox log rank tests were used to analyze survival curves (Prism, Graphpad). A *p* value of <0.05 was considered significant.

Conflict of interest: The authors declare no commercial or financial conflict of interest.

References

1 **Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J. et al.**, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J. Clin. Oncol.* 1999. **17**: 2105–2116.

2 **Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R. et al.**, Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.* 2010. **363**: 711–723.

3 **Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H. et al.**, Nivolumab plus ipilimumab in advanced melanoma. *N. Engl. J. Med.* 2013. **369**: 122–133.

4 **Mulé, J. J., Ettinghausen, S. E., Spiess, P. J., Shu, S. and Rosenberg, S. A.**, Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. *Cancer Res.* 1986. **46**: 676–683.

5 **Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L. et al.**, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 2002. **298**: 850–854.

6 **Hu, H.-M., Poehlein, C. H., Urba, W. J. and Fox, B. A.**, Development of antitumor immune responses in reconstituted lymphopenic hosts. *Cancer Res.* 2002. **62**: 3914–3919.

7 **Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. and June, C. H.**, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N. Engl. J. Med.* 2011. **365**: 725–733.

8 **Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E. et al.**, Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006. **314**: 126–129.

9 **Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S. and Papaioannou, V. E.**, RAG-1-deficient mice have no mature B and T lymphocytes. *Cell* 1992. **68**: 869–877.

10 **North, R. J.**, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. *J. Exp. Med.* 1982. **155**: 1063–1074.

11 **Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N. et al.**, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. *J. Exp. Med.* 2005. **202**: 907–912.

12 **Hinrichs, C. S., Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., Klebanoff, C. A. et al.**, Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. *Blood* 2011. **117**: 808–814.

13 **Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P., Ji, Y., Hinrichs, C. S., Borman, Z. A. et al.**, Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice. *Clin. Cancer Res.* 2011. **17**: 5343–5352.

14 **Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F. et al.**, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J. Clin. Oncol.* 2008. **26**: 5233–5239.

15 **Barth, R. J., Mulé, J. J., Spiess, P. J. and Rosenberg, S. A.**, Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. *J. Exp. Med.* 1991. **173**: 647–658.

16 **Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J.**, T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. *Nature* 1998. **393**: 480–483.

17 **Sun, J. C., Williams, M. A. and Bevan, M. J.**, CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. *Nat. Immunol.* 2004. **5**: 927–933.

18 **Hu, H. M., Winter, H., Urba, W. J. and Fox, B. A.**, Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. *J. Immunol.* 2000. **165**: 4246–4253.

19 **de Goër de Herve, M.-G., Cariou, A., Simonetta, F. and Taoufik, Y.**, Heterospecific CD4 help to rescue CD8 T cell killers. *J. Immunol.* 2008. **181**: 5974–5980.

20 **Kmieciak, M., Worschech, A., Nikizad, H., Gowda, M., Habibi, M., Depcrynski, A., Wang, E. et al.**, CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. *Breast Cancer Res. Treat.* 2011. **126**: 385–394.

21 **LaCelle, M. G., Jensen, S. M. and Fox, B. A.**, Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. *Clin. Cancer Res.* 2009. **15**: 6881–6890.

22 **Côté, A. L., Byrne, K. T., Steinberg, S. M., Zhang, P. and Turk, M. J.**, Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. *PLoS ONE* 2011. **6**: e26491.

23 **Tan, J. T., Ernst, B., Kieper, W. C., LeRoy, E., Sprent, J. and Surh, C. D.**, Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. *J. Exp. Med.* 2002. **195**: 1523–1532.

24 **Goldrath, A. W., Bogatzki, L. Y. and Bevan, M. J.**, Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. *J. Exp. Med.* 2000. **192**: 557–564.

25 **Cohen, P. A., Kim, H., Fowler, D. H., Gress, R. E., Jakobsen, M. K., Alexander, R. B., Mulé, J. J. et al.**, Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity. *J. Immunother. Emphasis Tumor Immunol.* 1993. **14**: 242–252.

26 **Curti, B. D., Ochoa, A. C., Powers, G. C., Kopp, W. C., Alvord, W. G., Janik, J. E., Gause, B. L. et al.**, Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. *J. Clin. Oncol.* 1998. **16**: 2752–2760.

27 **Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R. et al.**, Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. *J. Exp. Med.* 2010. **207**: 637–650.

28 **Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E. K. M., Muranski, P. et al.**, Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. *J. Exp. Med.* 2010. **207**: 651–667.

29 **Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al.**, Tumor-specific Th17-polarized cells eradicate large established melanoma. *Blood* 2008. **112**: 362–373.

30 **Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F. et al.**, gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N. Engl. J. Med.* 2011. **364**: 2119–2127.

31 **Robbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J. et al.**, Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. *J. Immunol.* 2004. **173**: 7125–7130.

32 **Precopio, M. L., Betts, M. R., Parrino, J., Price, D. A., Gostick, E., Ambrozak, D. R., Asher, T. E. et al.**, Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. *J. Exp. Med.* 2007. **204**: 1405–1416.

33 **Frankel, T. L., Burns, W. R., Peng, P. D., Yu, Z., Chinnasamy, D., Wargo, J. A., Zheng, Z. et al.**, Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. *J. Immunol.* 2010. **184**: 5988–5998.

34 **Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Born-stein, E., Asher, T. E. et al.**, Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. *J. Exp. Med.* 2007. **204**: 2473–2485.

35 **Hu, H.-M., Winter, H., Ma, J., Croft, M., Urba, W. J. and Fox, B. A.**, CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. *J. Immunol.* 2002. **169**: 4897–4904.

36 **Bos, R. and Sherman, L. A.**, CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. *Cancer Res.* 2010. **70**: 8368–8377.

37 **Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. and Heath, W. R.**, Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature* 1998. **393**: 478–480.

38 **Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S. et al.**, CD4 +T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. *Nature* 2005. **434**: 88–93.

39 **Rapetti, L., Meunier, S., Pontoux, C. and Tanchot, C.**, CD4 help regulates expression of crucial genes involved in CD8 T cell memory and sensitivity to regulatory elements. *J. Immunol.* 2008. **181**: 299–308.

40 **Aubert, R. D., Kamphorst, A. O., Sarkar, S., Vezys, V., Ha, S.-J., Barber, D. L., Ye, L. et al.**, Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. *Proc. Natl. Acad. Sci. USA* 2011. **108**: 21182–21187.

41 **Fuse, S., Tsai, C. Y., Molloy, M. J., Allie, S. R., Zhang, W., Yagita, H. and Usherwood, E. J.**, Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. *J. Immunol.* 2009. **182**: 4244–4254.

42 **Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H. et al.**, PD-1 blockade enhances T cell migration to tumors by elevating IFN-γ inducible chemokines. *Cancer Res.* 2012. **72**: 5209–5218.

43 **Nakanishi, Y., Lu, B., Gerard, C. and Iwasaki, A.**, CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. *Nature* 2009. **462**: 510–513.

44 **Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J. and Schreiber, R. D.**, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature* 2001. **410**: 1107–1111.

45 **Jensen, S. M., Twitty, C. G., Maston, L. D., Antony, P. A., Lim, M., Hu, H.-M., Petrausch, U. et al.**, Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. *J. Immunol.* 2012. **89**: 767–776.

46 **Knutson, K. L. and Disis, M. L.**, Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. *Cancer Immunol. Immunother.* 2005. **54**: 721–728.

47 **Butterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D., Wang, H.-J. et al.**, Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. *Clin. Cancer Res.* 2003. **9**: 998–1008.

48 **Hu, H. M., Urba, W. J. and Fox, B. A.**, Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. *J. Immunol.* 1998. **161**: 3033–3041.

49 **Quah, B. J. C, Warren, H. S. and Parish, C. R.**, Monitoring lympho-cyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. *Nat. Protoc.* 2007. **2**: 2049–2056.

Full correspondence: Dr. Bernard A. Fox, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, 2N56 North Pavilion, 4805 NE Glisan Street, Portland, OR 97213, USA
Fax: +1-503-215-6841
e-mail: foxb@foxlab.org